🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Jiatan Pharmatech clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Jiatan Pharmatech as lead sponsor. Synced 26 Sep 2026
5Current trials
5Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Jiatan Pharmatech is the lead sponsor of 5 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are WX390, Toripalimab and Bedaquiline. The most-studied condition is Solid Tumor.

ClinicalTrials.gov trials by status

  • Recruiting5100%

Trials by phase

  • Phase 2240%
  • Phase 1120%
  • Phase 3120%
  • Phase 1/2120%
01

Clinical trials sponsored by Shanghai Jiatan Pharmatech

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Pharmacokinetic Study of Sudapyridine(WX-081)in Healthy Chinese Subjects
NCT06701110 · ClinicalTrials.gov ↗ · TB
Phase 1 Recruiting 2024-09 China
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
NCT05824871 · ClinicalTrials.gov ↗ · Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)
Phase 3 Recruiting 2022-09 China
A Study of WX390 in Patients With Advanced Solid Tumors
NCT06117540 · ClinicalTrials.gov ↗ · Solid Tumor
Drug: WX390
Phase 2 Recruiting 2021-05 China
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT06117566 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Recruiting 2022-11 China
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
NCT06124963 · ClinicalTrials.gov ↗ · Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
Phase 2 Recruiting 2023-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Jiatan Pharmatech trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Jiatan Pharmatech trials

5 conditions
Solid Tumor2TB1Rifampin-Resistant Pulmonary Tuberculosis1Tuberculosis, Multidrug-Resistant (MDR-TB)1Gastric Type Adenocarcinoma (GAS) With STK11 Mutation1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China55

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Solid Tumor

SponsorTrials
Sichuan Baili Pharmaceutical23
Suzhou Suncadia Biopharmaceuticals4
Peking University Cancer Hospital & Institute3
Chinese PLA General Hospital3
Shenzhen Geno-Immune Medical Institute3
Shanghai Cell Therapy Group3
Hua Zhu3
Pyxis Oncology2
Tyra Biosciences2
Biohaven Therapeutics2

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Jiatan Pharmatech trials

How many clinical trials does Shanghai Jiatan Pharmatech sponsor?

Shanghai Jiatan Pharmatech is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Jiatan Pharmatech trials recruiting?

Yes. 5 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Jiatan Pharmatech testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are WX390 (3), Toripalimab (2) and Bedaquiline (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.